Zelig Eshhar, PhD

Zelig Eshhar, PhD

Zelig Eshhar, PhD 500 500 Cell Source, Inc.

Zelig Eshhar, PhD

Inventor of CAR-T
Initiated collaboration with Cell Source to develop allogenic CAR-T + Veto cell therapies
Weizmann Institute of Science (Israel)
Developer of core technology used by KITE Pharma (acquired by Gilead Sciences for $12B) and Juno Therapeutics (acquired by Cellgene, $9B) Professor of Chemical and Cellular Immunotherapy, Weizmann Institute of Science (Israel)
MD ANDERSON BIO
BACK TO PARTNERSHIPS

Subscribe to Cell Source’s Newsletter

    INVESTOR ALERTS. PRESS RELEASES. INDUSTRY & COMPANY NEWS.

    Get the latest Cell Source news and updates, delivered right to your inbox.

    SUBSCRIBE

    Copyright ©2023 Cell Source Inc. All Rights Reserved. Made by Corvus & Coil.

    Click here and enter your search term(s).